Table 3. Association between TIL CXCR3, CCR5 expression, CCR5-Δ32 polymorphism, and their interaction, with clinical outcome.
|
Model A (gene expression model): expression of
CXCR3
and
CCR5, and their interactions | |||
| Full model definition | Association with clinical outcome | ||
| Comparator | Outcome P-valuea | ||
| Full model A |
|
CR |
OR |
| Y∼u+x1+x2+x1x2 |
Y∼u |
0.032 |
0.15 |
|
Model B (gene expression/polymorphism model): expression of
CXCR3
and
CCR5, and
CCR5-Δ32 polymorphism | |||
| Full model definition | Association with clinical outcome | ||
| Comparator | Outcome P-valuea | ||
| Full model B |
|
CR |
OR |
| Y∼u+x1+x2+x3+x1x2+x1x3+x2x3+x1x2x3 | Y∼u | 0.0009 | 0.007 |
| |
Full model A |
0.003 |
0.007 |
|
Model C (gene expression and treatment model): treatment, expression of
CCR5and
CXCR3, and their interactions | |||
| Full model definition | Association with clinical outcome | ||
| Comparator | Outcome P-valuea | ||
| Full model C |
|
CR |
OR |
| Y∼u+Rx+x1+x2+x1x2 |
Y∼u+Rx |
0.002 |
0.010 |
|
Model D (gene expression/polymorphism and treatment model): treatment, expression of
CXCR3
and
CCR5, CCR5-Δ32 polymorphism, and their interactions | |||
| Full model definition | Association with clinical outcome | ||
| Comparator | Outcome P-valuea | ||
| Full model D |
|
CR |
OR |
| Y∼u+Rx+x1+x2+x3+x1x2+x1x3+x2x3+x1x2x3 | Y∼u+Rx | 0.0001 | 0.003 |
| Full Model C | 0.005 | 0.036 | |
Abbreviations: CR=complete response; OR=overall response; Rx=treatment (TNMA, T200, T1200, TYT, and TCD8); TIL=tumour-infiltrating lymphocyte; Y=end point (CR or OR); Y∼u=null model; X1=expression of CCR5; X2=expression of CXCR3; X3=CCR5-Δ32 polymorphism.
a
The log likelihood ratio test to was used to compare the fit of two models, one of which (the null model) is a special case of the other (the alternative model). The test is based on the log likelihood ratio, which expresses how many times more likely the data are under one model than the other. During the model fitting, the sample with missing genotype data was omitted.